Page 264 - Read Online

Cao Cancer Evo-Dev

with hepatitis B–related cirrhosis or hepatocellular carcinoma. J 46. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and
Gastroenterol 2010;45:1063-71. host inflammation-related factors that can predict the prognosis of
31. Liu S, Xie J, Yin J, Zhang H, Zhang Q, Pu R, Li C, Ni W, Wang H, hepatocellular carcinoma. Eur J Cancer 2012;48:1977-87.
Cao G. A matched case–control study of hepatitis B virus mutations 47. Yeh CT, So M, Ng J, Yang HW, Chang ML, Lai MW, Chen TC, Lin
in the preS and core promoter regions associated independently with CY, Yeh TS, Lee WC. Hepatitis B virus-DNA level and basal core
hepatocellular carcinoma. J Med Virol 2011;83:45-53. promoter A1762T/G1764A mutation in liver tissue independently
32. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations predict postoperative survival in hepatocellular carcinoma.
between hepatitis B virus mutations and the risk of hepatocellular Hepatology 2010;52:1922-33.
carcinoma: a meta-analysis. J Natl Cancer Inst 2009;101:1066-82. 48. Wu TJ, Chan KM, Chou HS, Lee CF, Wu TH, Chen TC, Yeh CT, Lee
33. Yin J, Wang J, Pu R, Xin H, Li Z, Han X, Ding Y, Du Y, Liu W, WC. Liver transplantation in patients with hepatitis B virus-related
Deng Y, Ji X, Wu M, Yu M, Zhang H, Wang H, Thompson TC, Ni W, hepatocellular carcinoma: the influence of viral characteristics on
Cao G. Hepatitis B virus combo mutations improve the prediction and clinical outcome. Ann Surg Oncol 2013;20:3582-90.
active prophylaxis of hepatocellular carcinoma: a clinic-based cohort 49. Mathews P, Lee D, Chung YH, Kim JA, Lee JH, Jin YJ, Park W, Lyu
study. Cancer Prev Res (Phila) 2015;8:978-88. H, Jaffee E, Zheng L, Yu E, Lee YJ. Effects of genomic changes in
34. Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, Fang hepatitis B virus on postoperative recurrence and survival in patients
KX, Yang JY, Wang XY, Harrison TJ. HBV A1762T, G1764A with hepatocellular carcinoma. Ann Surg Oncol 2013;20:1216-22.
mutations are a valuable biomarker for identifying a subset of male 50. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT.
HBsAg carriers at extremely high risk of hepatocellular carcinoma: a Association between nucleoside analogues and risk of hepatitis B
prospective study. Am J Gastroenterol 2008;103:2254-62. virus-related hepatocellular carcinoma recurrence following liver
35. Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, Shih WL, resection. JAMA 2012;308:1906-14.
Chen PJ, Liaw YF, Chen CJ. Temporal relationship between hepatitis 51. Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang
B virus enhancer II/basal core promoter sequence variation and risk of H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/
hepatocellular carcinoma. Gut 2008;57:91-7. nucleoside analogs on postoperative prognosis of hepatitis B virus-
36. Bai X, Zhu Y, Jin Y, Guo X, Qian G, Chen T, Zhang J, Wang J, related hepatocellular carcinoma: a two-stage longitudinal clinical
Groopman JD, Gu J, Tu H. Temporal acquisition of sequential study. J Clin Oncol 2013;31:3647-55.
mutations in the enhancer II and basal core promoter of HBV in 52. Huang S, Xia Y, Lei Z, Zou Q, Li J, Yang T, Wang K, Yan Z, Wan
individuals at high risk for hepatocellular carcinoma. Carcinogenesis X, Shen F. Antiviral therapy inhibits viral reactivation and improves
2011;32:63-8. survival after repeat hepatectomy for hepatitis B virus-related recurrent
37. Sung FY, Lan CY, Huang CJ, Lin CL, Liu CJ, Chen PJ, Lin SM, hepatocellular carcinoma. J Am Coll Surg 2017;224:283-93.e4.
Yu MW. Progressive accumulation of mutations in the hepatitis B 53. Du Y, Su T, Ding Y, Cao G. Effects of antiviral therapy on the
virus genome and its impact on time to diagnosis of hepatocellular recurrence of hepatocellular carcinoma after curative resection or liver
carcinoma. Hepatology 2016;64:720-31. transplantation. Hepat Mon 2012;12:e6031.
38. Li Z, Xie Z, Ni H, Zhang Q, Lu W, Yin J, Liu W, Ding Y, Zhao Y, 54. Chen CH, Hung CH, Lee CM, Hu TH, Wang JH, Wang JC, Lu SN,
Zhu Y, Pu R, Zhang H, Dong H, Fu Y, Sun Q, Xu G, Cao G. Mother- Changchien CS. Pre-S deletion and complex mutations of hepatitis B
to-child transmission of hepatitis B virus: evolution of hepatocellular virus related to advanced liver disease in HBeAg-negative patients.
carcinoma-related viral mutations in the post-immunization era. J Clin Gastroenterology 2007;133:1466-74.
Virol 2014;61:47-54. 55. Liu WC, Wu IC, Lee YC, Lin CP, Cheng JH, Lin YJ, Yen CJ, Cheng
39. Maman Y, Blancher A, Benichou J, Yablonka A, Efroni S, Louzoun PN, Li PF, Cheng YT, Cheng PW, Sun KT, Yan SL, Lin JJ, Yang
Y. Immune-induced evolutionary selection focused on a single reading JC, Chang KC, Ho CH, Tseng VS, Chang BC, Wu JC, Chang TT.
frame in overlapping hepatitis B virus proteins. J Virol 2011;85:4558- Hepatocellular carcinoma-associated single-nucleotide variants and
66. deletions identified by the use of genome-wide high-throughput
40. Tran A, Kremsdorf D, Capel F, Housset C, Dauguet C, Petit MA, analysis of hepatitis B virus. J Pathol 2017;243:176-92.
Brechot C. Emergence of and takeover by hepatitis B virus (HBV) 56. Huang Y, Tong S, Tai AW, Hussain M, Lok AS. Hepatitis B
with rearrangements in the pre-S/S and pre-C/C genes during chronic virus core promoter mutations contribute to hepatocarcinogenesis
HBV infection. J Virol 1991;65:3566-74. by deregulating SKP2 and its target, p21. Gastroenterology
41. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, 2011;141:1412-21, 1421.e1-5.
McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl 57. Huang Y, Tai AW, Tong S, Lok AS. HBV core promoter mutations
Acad Sci U S A 1996;93:4398-402. promote cellular proliferation through E2F1-mediated upregulation
42. Orito E, Mizokami M, Ina Y, Moriyama EN, Kameshima N, of S-phase kinase-associated protein 2 transcription. J Hepatol
Yamamoto M, Gojobori T. Host-independent evolution and a 2013;58:1068-73.
genetic classification of the hepadnavirus family based on nucleotide 58. Mun HS, Lee SA, Kim H, Hwang ES, Kook YH, Kim BJ. Novel
sequences. Proc Natl Acad Sci U S A 1989;86:7059-62. F141L pre-S2 mutation in hepatitis B virus increases the risk of
43. Vartanian JP, Henry M, Marchio A, Suspene R, Aynaud MM, Guetard hepatocellular carcinoma in patients with chronic genotype C
D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, infections. J Virol 2011;85:123-32.
Dejean A, Wain-Hobson S. Massive APOBEC3 editing of hepatitis B 59. Wang Y, Lau SH, Sham JS, Wu MC, Wang T, Guan XY.
viral DNA in cirrhosis. PLoS Pathog 2010;6:e1000928. Characterization of HBV integrants in 14 hepatocellular carcinomas:
44. Xu R, Zhang X, Zhang W, Fang Y, Zheng S, Yu XF. Association association of truncated X gene and hepatocellular carcinogenesis.
of human APOBEC3 cytidine deaminases with the generation of Oncogene 2004;23:142-8.
hepatitis virus B x antigen mutants and hepatocellular carcinoma. 60. Sze KM, Chu GK, Lee JM, Ng IO. C-terminal truncated hepatitis
Hepatology 2007;46:1810-20. B virus x protein is associated with metastasis and enhances
45. Yang F, Ma LT, Cao GW. Hepatocellular carcinoma: co-evolution of invasiveness by C-Jun/matrix metalloproteinase protein 10 activation
hepatocytes and hepatitis B virus. Chin J Hepatol 2017;25:321-4. (in in hepatocellular carcinoma. Hepatology 2013;57:131-9.
Chinese) 61. Zhang Q, Yin J, Zhang Y, Deng Y, Ji X, Du Y, Pu R, Han Y, Zhao

256 Hepatoma Research ¦ Volume 3 ¦ October 27, 2017